{"id":54822,"date":"2023-03-14T16:04:18","date_gmt":"2023-03-14T15:04:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/"},"modified":"2023-03-14T16:04:18","modified_gmt":"2023-03-14T15:04:18","slug":"market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/","title":{"rendered":"Market Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations"},"content":{"rendered":"
\n

ATLANTA–(BUSINESS WIRE)–#Biotech<\/a>–Axion BioSystems vigorously refutes a recent filing by Agilent Technologies, Inc. (NYSE: A) claiming patent infringement and false advertising.\n<\/p>\n

<\/a><\/p>\n

\nAs a recognized biotechnology innovator and owner of numerous patents over 14 years, Axion BioSystems expects its competitors to respect its intellectual property rights, just as Axion respects the intellectual property rights of its competitors. But when competitors make allegations that are without merit, Axion must robustly defend itself.\n<\/p>\n

\nAt issue are Agilent Technologies, Inc.\u2019s spurious allegations of false advertising and claims that certain of Axion\u2019s live-cell analysis products infringe three Agilent patents. In rebuttal, Axion rejects any claims of patent infringement and stands by the technological capabilities of its products.\n<\/p>\n

\nAxion is confident that it does not infringe Agilent\u2019s patents and that those patents will ultimately be proven invalid. Axion looks forward to vindicating its rights in court and obtaining a successful outcome against Agilent. Axion BioSystems will continue to advance the frontiers of live-cell analysis as a market innovator to accelerate biomedical discoveries.\n<\/p>\n

\nAbout Axion BioSystems<\/b>\n<\/p>\n

\nAxion BioSystems<\/a>, Inc. is a leading life science company focused on next-generation live-cell analysis tools for biomedical research and drug discovery. With innovative systems that monitor complex cellular activity in real time without disturbing the underlying biology, Axion\u2019s technology accelerates scientific discovery with streamlined workflows providing more complete datasets. Headquartered in Atlanta, Georgia, USA, the company has more than 180 employees worldwide. www.axionbiosystems.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMike Clements
\n
Vice President Marketing, Axion BioSystems
\n
media@axionbio.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ATLANTA–(BUSINESS WIRE)–#Biotech–Axion BioSystems vigorously refutes a recent filing by Agilent Technologies, Inc. (NYSE: A) claiming patent infringement and false advertising. As a recognized biotechnology innovator and owner of numerous patents over 14 years, Axion BioSystems expects its competitors to respect its intellectual property rights, just as Axion respects the intellectual property rights of its competitors. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54822","6":"format-standard","7":"category-industry"},"yoast_head":"\nMarket Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Market Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ATLANTA–(BUSINESS WIRE)–#Biotech–Axion BioSystems vigorously refutes a recent filing by Agilent Technologies, Inc. (NYSE: A) claiming patent infringement and false advertising. As a recognized biotechnology innovator and owner of numerous patents over 14 years, Axion BioSystems expects its competitors to respect its intellectual property rights, just as Axion respects the intellectual property rights of its competitors. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-14T15:04:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230314005263\/en\/1737082\/21\/Axion_logo_-_Brand_-_Registered_Trademark.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Market Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations\",\"datePublished\":\"2023-03-14T15:04:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\\\/\"},\"wordCount\":258,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005263\\\/en\\\/1737082\\\/21\\\/Axion_logo_-_Brand_-_Registered_Trademark.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\\\/\",\"name\":\"Market Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005263\\\/en\\\/1737082\\\/21\\\/Axion_logo_-_Brand_-_Registered_Trademark.jpg\",\"datePublished\":\"2023-03-14T15:04:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005263\\\/en\\\/1737082\\\/21\\\/Axion_logo_-_Brand_-_Registered_Trademark.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005263\\\/en\\\/1737082\\\/21\\\/Axion_logo_-_Brand_-_Registered_Trademark.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Market Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Market Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/","og_locale":"en_US","og_type":"article","og_title":"Market Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations - Pharma Trend","og_description":"ATLANTA–(BUSINESS WIRE)–#Biotech–Axion BioSystems vigorously refutes a recent filing by Agilent Technologies, Inc. (NYSE: A) claiming patent infringement and false advertising. As a recognized biotechnology innovator and owner of numerous patents over 14 years, Axion BioSystems expects its competitors to respect its intellectual property rights, just as Axion respects the intellectual property rights of its competitors. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-14T15:04:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230314005263\/en\/1737082\/21\/Axion_logo_-_Brand_-_Registered_Trademark.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Market Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations","datePublished":"2023-03-14T15:04:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/"},"wordCount":258,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230314005263\/en\/1737082\/21\/Axion_logo_-_Brand_-_Registered_Trademark.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/","url":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/","name":"Market Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230314005263\/en\/1737082\/21\/Axion_logo_-_Brand_-_Registered_Trademark.jpg","datePublished":"2023-03-14T15:04:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230314005263\/en\/1737082\/21\/Axion_logo_-_Brand_-_Registered_Trademark.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230314005263\/en\/1737082\/21\/Axion_logo_-_Brand_-_Registered_Trademark.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/market-disruptor-axion-biosystems-rejects-agilent-technologies-inc-allegations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Market Disruptor Axion BioSystems Rejects Agilent Technologies, Inc. Allegations"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54822"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54822\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54822"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54822"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}